Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).
Journal: Journal of neurology
Published: February 22, 2026
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases.
Journal: Expert review of clinical immunology
Published: April 29, 2025
Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG).
Journal: BMJ open
Published: May 11, 2023
Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG.
Journal: BMJ open
Published: January 31, 2023
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.
Journal: American journal of hematology
Published: October 22, 2019
Showing 1-6 of 6
Last Updated: 09/26/2026